BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 25269710)

  • 21. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.
    Labirua-Iturburu A; Selva-O'Callaghan A; Martínez-Gómez X; Trallero-Araguás E; Labrador-Horrillo M; Vilardell-Tarrés M
    Clin Exp Rheumatol; 2013; 31(3):436-9. PubMed ID: 23465087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort.
    Chua F; Higton AM; Colebatch AN; O'Reilly K; Grubnic S; Vlahos I; Edwards CJ; Kiely PD
    Rheumatology (Oxford); 2012 Oct; 51(10):1870-6. PubMed ID: 22763991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
    Srivastava P; Dwivedi S; Misra R
    Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.
    Marie I; Josse S; Decaux O; Dominique S; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Tiev KP; Vittecoq O; Noel D; Mouthon L; Menard JF; Jouen F
    Autoimmun Rev; 2012 Aug; 11(10):739-45. PubMed ID: 22326685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between anti-PL7 antibodies and increased fibrotic component in patients with antisynthetase syndrome and interstitial lung disease: a cross-sectional study.
    Rivero-Gallegos D; Mejía M; Rocha-González HI; Huerta-Cruz JC; Falfán-Valencia R; Ramos-Martínez E; Mateos-Toledo HN; Castillo-López MF; Rodríguez-Torres YK; Lira-Boussart V; Rojas-Serrano J
    Clin Rheumatol; 2024 Jun; 43(6):1971-1978. PubMed ID: 38642252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China.
    Wang R; Zhao Y; Qi F; Wu X; Wang Y; Xu Y; Wu Y; Zhang N; Hou H; Sun W; Li X; Wei W
    Clin Rheumatol; 2023 Mar; 42(3):703-709. PubMed ID: 36308573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy.
    Huang HL; Lin WC; Yeh CC; Sun YT
    J Clin Neurosci; 2020 Apr; 74():32-35. PubMed ID: 31982271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
    Hervier B; Devilliers H; Stanciu R; Meyer A; Uzunhan Y; Masseau A; Dubucquoi S; Hatron PY; Musset L; Wallaert B; Nunes H; Maisonobe T; Olsson NO; Adoue D; Arlet P; Sibilia J; Guiguet M; Lauque D; Amoura Z; Hachulla E; Hamidou M; Benveniste O
    Autoimmun Rev; 2012 Dec; 12(2):210-7. PubMed ID: 22771754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC; Cottin V; Fabien N; Thivolet-Béjui F; Cordier JF
    J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature.
    Labirua-Iturburu A; Selva-O'Callaghan A; Vincze M; Dankó K; Vencovsky J; Fisher B; Charles P; Dastmalchi M; Lundberg IE
    Medicine (Baltimore); 2012 Jul; 91(4):206-211. PubMed ID: 22732951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of myositis autoantibody in patients with idiopathic interstitial lung disease.
    Song JS; Hwang J; Cha HS; Jeong BH; Suh GY; Chung MP; Kang ES
    Yonsei Med J; 2015 May; 56(3):676-83. PubMed ID: 25837172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.
    Johnson C; Pinal-Fernandez I; Parikh R; Paik J; Albayda J; Mammen AL; Christopher-Stine L; Danoff S
    Lung; 2016 Oct; 194(5):733-7. PubMed ID: 27166633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease.
    Cobo-Ibáñez T; López-Longo FJ; Joven B; Carreira PE; Muñoz-Fernández S; Maldonado-Romero V; Larena-Grijalba C; Cubas IL; Muriel ET; Mateos CB; de la Peña Lefebvre PG; Gomez-Gomez A; Nogal LB; Pérez A; Almodovar R; Lojo L; Ruiz-Gutiérrez L; López-Robledillo JC; García de Yébenes MJ; Nuño-Nuño L
    Clin Rheumatol; 2019 Mar; 38(3):803-815. PubMed ID: 30392161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome.
    Marie I; Josse S; Decaux O; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Hachulla E; Vittecoq O; Menard JF; Jouen F; Dominique S
    Eur J Intern Med; 2013 Jul; 24(5):474-9. PubMed ID: 23375620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.
    Laporte A; Mariampillai K; Allenbach Y; Pasi N; Donciu V; Toledano D; Granger B; Benveniste O; Grenier PA; Boussouar S
    Eur Radiol; 2022 May; 32(5):3480-3489. PubMed ID: 35022809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies.
    Misra AK; Wong NL; Healey TT; Lally EV; Shea BS
    BMC Pulm Med; 2021 Nov; 21(1):370. PubMed ID: 34775966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review.
    Liu Y; Liu X; Xie M; Chen Z; He J; Wang Z; Dai J; Cai H
    Respir Med; 2020; 165():105920. PubMed ID: 32174452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase.
    Hirakata M; Suwa A; Takada T; Sato S; Nagai S; Genth E; Song YW; Mimori T; Targoff IN
    Arthritis Rheum; 2007 Apr; 56(4):1295-303. PubMed ID: 17393393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.
    Pinal-Fernandez I; Casal-Dominguez M; Huapaya JA; Albayda J; Paik JJ; Johnson C; Silhan L; Christopher-Stine L; Mammen AL; Danoff SK
    Rheumatology (Oxford); 2017 Jun; 56(6):999-1007. PubMed ID: 28339994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
    Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
    Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.